Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares Acquired by Long Focus Capital Management LLC

Long Focus Capital Management LLC increased its position in shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) by 15.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,346,417 shares of the biotechnology company's stock after acquiring an additional 1,662,184 shares during the period. Long Focus Capital Management LLC owned about 5.00% of Adaptimmune Therapeutics worth $12,037,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Renaissance Technologies LLC increased its stake in Adaptimmune Therapeutics by 28.3% during the 2nd quarter. Renaissance Technologies LLC now owns 1,786,341 shares of the biotechnology company's stock worth $1,742,000 after buying an additional 394,566 shares during the period. Boulder Hill Capital Management LP acquired a new stake in shares of Adaptimmune Therapeutics in the first quarter valued at $143,000. JTC Employer Solutions Trustee Ltd acquired a new stake in shares of Adaptimmune Therapeutics in the first quarter valued at $41,000. Columbia Advisory Partners LLC purchased a new position in Adaptimmune Therapeutics in the first quarter valued at $25,000. Finally, Twin Focus Capital Partners LLC acquired a new position in Adaptimmune Therapeutics during the 4th quarter worth $44,000. Institutional investors and hedge funds own 31.37% of the company's stock.

Adaptimmune Therapeutics Stock Up 4.3 %

Shares of NASDAQ:ADAP traded up $0.04 on Friday, hitting $0.98. 1,116,195 shares of the company's stock were exchanged, compared to its average volume of 1,730,362. The company has a debt-to-equity ratio of 0.26, a quick ratio of 3.09 and a current ratio of 3.09. Adaptimmune Therapeutics plc has a 1-year low of $0.42 and a 1-year high of $2.05. The company has a market capitalization of $241.20 million, a PE ratio of -1.32 and a beta of 2.21. The firm's 50-day moving average is $1.13 and its 200 day moving average is $1.15.

Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) last announced its quarterly earnings results on Monday, August 12th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter. Adaptimmune Therapeutics had a negative return on equity of 116.80% and a negative net margin of 51.25%. The firm had revenue of $128.23 million during the quarter, compared to the consensus estimate of $58.00 million. Sell-side analysts predict that Adaptimmune Therapeutics plc will post -0.23 EPS for the current year.

Analyst Ratings Changes

ADAP has been the topic of a number of analyst reports. StockNews.com raised Adaptimmune Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, August 13th. Scotiabank assumed coverage on shares of Adaptimmune Therapeutics in a report on Thursday, May 30th. They issued a "sector outperform" rating and a $3.15 target price on the stock. Finally, HC Wainwright reiterated a "buy" rating and set a $4.00 price target on shares of Adaptimmune Therapeutics in a report on Tuesday, August 13th.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.